Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. The firm is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Follow-Up Questions
What is Haemonetics Corp (HAE)'s P/E Ratio?
The P/E ratio of Haemonetics Corp is 14.1217
Who is the CEO of Haemonetics Corp?
Mr. Christopher Simon is the President of Haemonetics Corp, joining the firm since 2016.
What is the price performance of HAE stock?
The current price of HAE is $49.75, it has decreased 1.23% in the last trading day.
What are the primary business themes or industries for Haemonetics Corp?
Haemonetics Corp belongs to Health Care industry and the sector is Health Care
What is Haemonetics Corp market cap?
Haemonetics Corp's current market cap is $2.3B
Is Haemonetics Corp a buy, sell, or hold?
According to wall street analysts, 12 analysts have made analyst ratings for Haemonetics Corp, including 5 strong buy, 7 buy, 2 hold, 1 sell, and 5 strong sell
